108 results on '"Girard, Bethany"'
Search Results
2. Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
3. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
4. Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial
5. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial
6. Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
7. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
8. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
9. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
10. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
11. Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients.
12. Safety and Immunogenicity of an mRNA-Based hMPV/PIV3 Combination Vaccine in Seropositive Children
13. Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters
14. Long-term safety and efficacy of COVE study open-label and booster phases
15. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial
16. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines.
17. Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines
18. 2655. Phase 1 Safety and Immunogenicity Results of Two Investigational mRNA Vaccines, mRNA-1345, a Respiratory Syncytial Virus Vaccine, and mRNA-1653, a Human Metapneumovirus and Parainfluenza Virus Type 3 Combination Vaccine in Seropositive Young Children
19. 367. Safety and Immunogenicity of a 50-μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in Adolescents
20. 2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial
21. Immunostimulatory/immunodynamic model of mRNA-1273 to guide pediatric vaccine dose selection
22. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
23. Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines
24. Mutational basis of serum cross-neutralization profiles elicited by infection or vaccination with SARS-CoV-2 variants
25. Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters
26. A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273
27. Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19
28. Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
29. LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
30. Three-month Antibody Persistence of a Bivalent Omicron-containing Booster Vaccine Against COVID-19
31. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
32. A Bivalent Omicron-Containing Booster Vaccine against Covid-19
33. Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
34. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
35. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
36. Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial
37. Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine
38. Negative Immune Checkpoint Protein, VISTA, Regulates the CD4+ Treg Population During Sepsis Progression to Promote Acute Sepsis Recovery and Survival
39. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
40. mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children
41. Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
42. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
43. Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
44. Initial Analysis of Viral Dynamics and Circulating Viral Variants During the mRNA-1273 Phase 3 COVE Trial
45. Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge
46. Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial
47. Negative Immune Checkpoint Protein, VISTA, Regulates the CD4+ Treg Population During Sepsis Progression to Promote Acute Sepsis Recovery and Survival.
48. A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis
49. PAD4 Deficiency Limits Kidney Dysregulation in a Murine Model of Shock/Sepsis
50. Immunostimulatory/Immunodynamic model of mRNA‐1273 to guide pediatric vaccine dose selection.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.